Trials / Active Not Recruiting
Active Not RecruitingNCT05768347
Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
Phase 1 Clinical Trial of Intravesical Adoptive Cell Therapy {ACT) With Tumor Infiltrating Lymphocytes (TIL) for Patients With BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer (NMIBC)
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL) | Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies. |
Timeline
- Start date
- 2023-08-10
- Primary completion
- 2025-10-10
- Completion
- 2027-01-01
- First posted
- 2023-03-14
- Last updated
- 2025-12-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05768347. Inclusion in this directory is not an endorsement.